Streetbeat News

Regulatory

EWU

TSLA

VGK

The European Union is reportedly planning to propose a three-year delay on tariffs for electric vehicle (EV) trade with the UK. This move could significantly impact the EV industry, providing manufacturers with more time to adjust to the post-Brexit trading environment and potentially benefiting companies that trade between the EU and UK.

Portfolio Pulse from Benzinga Newsdesk

December 05, 2023 | 3:17 pm

HON

Illinois Representative Jonathan Jackson reported selling Honeywell Intl (NASDAQ:HON) stock valued between $50,001 and $100,000 on December 4, 2023. Honeywell shares are slightly down by 0.3% at $197.77. Congressional transactions are monitored under the STOCK Act and are not primary indicators for investing decisions but can be considered by investors. The reason for Jackson's sale is not specified, and such sales can have various motivations.

Portfolio Pulse from Benzinga Insights

December 05, 2023 | 3:05 pm

MSFT

NVDA

Shanghai authorities have requested Microsoft Corp (NASDAQ:MSFT) to enhance AI technology use in local businesses. The city is also interested in collaborating with Microsoft on technology governance frameworks. Meanwhile, Nvidia Corp (NASDAQ:NVDA) is testing a less powerful chip, the HGX H20, in China due to a U.S. embargo, and plans to release a specialized AI chip for China by Q1 2024. MSFT shares saw a slight increase.

Portfolio Pulse from Anusuya Lahiri

December 05, 2023 | 3:02 pm

AAPL

BLK

EADSY

ERIC

IBM

META

MMSI

MSFT

MSTR

NIO

TSLA

Cryptocurrencies Bitcoin, Ethereum, and Dogecoin experienced a spike due to 'panic buying' and a weak dollar. BlackRock received seed funding for a Bitcoin ETF, and MicroStrategy profited as Bitcoin rallied. In Brazil, legislation drafted by ChatGPT was passed unanimously. In the US, stocks like Merit Medical Systems moved lower in pre-market, while investor sentiment remained in the 'greed' zone. Tech companies like IBM, Meta, and Microsoft announced significant developments. Electric vehicle companies like Nio, Tesla, and Ford reported on sales and legal challenges. General Motors and Dave & Buster's faced business hurdles, while Ericsson secured a major deal. Airbus is close to its 2023 delivery target.

Portfolio Pulse from Akanksha Bakshi

December 05, 2023 | 2:21 pm

PTPI

Petros Pharmaceuticals has partnered with Idea Evolver, the sole provider to have successfully completed an Actual Use Trial for FDA review, which is necessary for Rx-to-OTC switch approval. This partnership is related to the over-the-counter (OTC) switch technology for the blockbuster cholesterol drug Crestor.

Portfolio Pulse from Benzinga Newsdesk

December 05, 2023 | 2:17 pm

VLD

Velo3D, Inc. (VLD) announced its Sapphire family of 3D printers are the first to achieve the U.S. Department of Defense's Green-level STIG Compliance, allowing connection to DoD's SIPRNet and NIPRNet. This certification ensures the printers are protected against cyberattacks, simplifies the management process, and makes it easier for defense contractors and agencies to purchase the printers. Velo3D's printers, including Sapphire, Sapphire 1MZ, Sapphire XC, and Sapphire XC 1MZ, exceeded the DoD's security threshold with an average score of 97% on tests.

Portfolio Pulse from Benzinga Newsdesk

December 05, 2023 | 2:12 pm

SAGE

Sage Therapeutics announced that its investigational drug SAGE-718 has been granted the nonproprietary name 'Dalzanemdor'. This is a key step in the drug development process, indicating progress towards potential commercialization. The new name will be used in clinical trials and future marketing.

Portfolio Pulse from Benzinga Newsdesk

December 05, 2023 | 2:10 pm

CDTX

Melinta Therapeutics and Cidara Therapeutics (NASDAQ:CDTX) announced the publication of pooled data from the ReSTORE Phase 3 and STRIVE Phase 2 trials of REZZAYO in The Lancet ID, demonstrating its efficacy and safety for treating candidemia and invasive candidiasis. REZZAYO, a once-weekly echinocandin, was approved by the FDA on March 22, 2023, for adults with limited treatment options and received a CMS J-Code and NTAP. Melinta acquired U.S. commercial rights from Cidara, who retains rights in Japan and licensed rights elsewhere to Melinta and Mundipharma. The EMA is reviewing the MAA for rezafungin.

Portfolio Pulse from Benzinga Newsdesk

December 05, 2023 | 2:08 pm

Procter & Gamble has announced in an SEC 8K filing that it anticipates incurring additional restructuring charges ranging from $1 billion to $1.5 billion after tax.

Portfolio Pulse from Benzinga Newsdesk

December 05, 2023 | 2:06 pm